CTD versus ATD in Letrozole Generic Dossier Submissions: A Comparative Regulatory Analysis and Framework for Harmonization

Nishtha Malara*, Anju Goyal

Bhupal Nobles' College of Pharmacy, Bhupal Nobles' University, Udaipur - 313001, Rajasthan, India

*Correspondence: nishthamalara02@gmail.com

DOI: https://doi.org/10.71431/IJRPAS.2026.5719            

INTRODUCTION:

Letrozole is a nonsteroidal aromatase inhibitor primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Approved by the FDA in the late 1990s, letrozole has become a cornerstone therapeutic option in both adjuvant and metastatic settings. The drug functions by inhibiting the aromatase enzyme (CYP19A1), which converts androgens to estrogens, thereby reducing estrogen levels and limiting the growth stimulus for estrogen-dependent tumours [1,2].

Global regulatory submissions for generic letrozole often require adapting the same scientific data package into multiple dossier formats. Two widely used systems, the ASEAN Technical Dossier and the ICH Common Technical Document, differ significantly in structure, regulatory expectations, and data-depth requirements. Understanding these differences is important because letrozole's long half-life (2-4 days), sensitivity to impurities, and strict bioequivalence requirements interact differently with each format's regulatory expectations [3-5].

Several prior publications have compared CTD requirements across ICH regions (for example, the United States, the European Union, and Australia) or have reviewed ATD implementation within individual ASEAN member states in isolation [2,14]. What has been comparatively underexplored is a drug-specific, side-by-side reading of the two formats for a single, clinically important oncology generic. This review addresses that gap by using letrozole as a working example to trace how CTD and ATD structural choices translate into concrete differences in quality documentation, stability reporting expectations, and case-level review experience, rather than treating the two formats only at the level of abstract module lists. The intended contribution is therefore practical: a reference point that pharmaceutical regulatory affairs teams preparing a letrozole-type generic submission can use to anticipate where the two pathways diverge.

Current Global Regulatory Harmonisation Efforts

International harmonisation of pharmaceutical regulatory requirements has advanced substantially since the founding of the International Council for Harmonisation (ICH), which brings together regulatory authorities and industry associations to develop unified guidance on quality, safety, and efficacy documentation. Parallel regional efforts, including the ASEAN Common Technical Dossier initiative, the Pan American Network for Drug Regulatory Harmonization, and the African Medicines Agency, illustrate a broader global trend toward reducing duplicative submission work for manufacturers operating across multiple jurisdictions [12,16]. However, the pace and depth of harmonisation vary considerably between regions with mature, ICH-aligned regulatory infrastructure and regions where national authorities retain substantial discretion over dossier content and format.

Existing Knowledge Gaps

Despite the ATD's stated goal of aligning ASEAN submission requirements with the ICH CTD, the practical, product-level consequences of the differences that remain are not well documented in the published literature. Specifically, there is limited comparative discussion of how module-wise structural differences affect the presentation of quality and stability data, how administrative and electronic-submission variability across ASEAN member states affects submission planning, and what specific harmonisation steps would most directly ease dossier preparation for oncology generics such as letrozole. This review is positioned to help close that gap.

Pharmacological Profile of Letrozole

Mechanism of action: Letrozole binds competitively and reversibly to the heme group of the aromatase enzyme, inhibiting its activity. This inhibition leads to substantial decreases in estrogen biosynthesis in peripheral tissues, particularly adipose tissue, which is the primary site of estrogen production in postmenopausal women [5,7].

Pharmacokinetics: Letrozole demonstrates high oral bioavailability, with peak plasma concentrations reached within 1-2 hours post-dose. Plasma protein binding is approximately 60%, primarily to albumin. Metabolism occurs predominantly via hepatic CYP3A4 and CYP2A6 pathways. The elimination half-life ranges between 2-4 days, supporting once-daily dosing, with steady-state achieved within 2-6 weeks; excretion occurs primarily via urine [8,9].

Pharmacodynamics: Letrozole produces rapid and sustained suppression of plasma estrogen levels. This estrogen depletion leads to decreased stimulation of estrogen receptor-positive breast cancer cells, inhibiting tumour progression [10].

Therapeutic indications: Letrozole is indicated for adjuvant therapy in early breast cancer, neoadjuvant therapy for locally advanced disease, first-line treatment of metastatic breast cancer, extended adjuvant therapy following tamoxifen, and off-label fertility treatment for ovulation induction [11].

Research Objectives

The primary aim of this work is to critically evaluate regulatory challenges encountered in letrozole dossier submissions, with specific focus on identifying key differences, requirements, and compliance issues between ATD and CTD formats. Specific objectives are to:

●       Analyse and compare the structural and content requirements of ATD and CTD for letrozole submissions.

●       Identify regulatory hurdles and inconsistencies faced by pharmaceutical companies preparing letrozole dossiers for ASEAN markets versus ICH-compliant regions.

●       Assess the impact of these regulatory differences on approval timelines, quality assurance, and market access.

●       Propose recommendations for harmonising dossier submission processes and improving regulatory compliance across jurisdictions.

MATERIALS AND METHODS

Study Design

This study adopts a qualitative, comparative regulatory analysis design intended to evaluate dossier submission requirements for letrozole across the CTD and ATD frameworks. The design combines a descriptive reading of each format's official structure with a critical, comparative assessment of how the two frameworks diverge in practice.

Literature Search Strategy

Sources were identified through a narrative (non-systematic) search of regulatory agency websites and general scientific literature databases, using search terms combining "letrozole", "Common Technical Document", "ASEAN Technical Dossier", "CTD", "ATD", "generic dossier submission", and "regulatory harmonisation". Regulatory guidance and technical documents were prioritised over secondary commentary. Searches were limited to English-language sources.

Data Sources

●       Official regulatory guidelines, acts, rules, and dossier submission templates applicable to letrozole from ASEAN regulatory authorities, CDSCO, and ICH regions.

●       Publicly available letrozole assessment reports, drug monographs, and EPAR/USFDA summaries.

●       Published regulatory guidance notes, technical reports, and industry white papers.

●       Peer-reviewed articles and regulatory case commentaries on letrozole evaluation, safety, efficacy, and quality documentation.

●       International harmonisation guidelines (ICH M4, Q-series, S-series) for dossier component coverage.

Inclusion and Exclusion Criteria

Inclusion criteria: documents relating to letrozole chemistry, manufacturing, control, safety, efficacy or pharmacology; national and international acts, rules, guidelines and CTD/ATD standards; literature published between 2000 and 2025.

Exclusion criteria: non-regulatory articles not relevant to dossier evaluation; duplicate studies; patents unless directly related to regulatory submissions.

Comparative Analysis Procedure

The comparative analysis proceeded in three steps. First, applicable acts, guidelines and dossier modules/parts were catalogued under quality, non-clinical, and clinical/safety categories for both frameworks. Second, key dossier elements for letrozole (API details and Drug Master File requirements, finished-product CMC data, stability data, bioequivalence requirements, and labelling/pharmacovigilance requirements) were extracted and mapped to the corresponding location in each format. Third, a requirement-by-requirement comparison was performed to identify missing, additional, or conflicting requirements, harmonisation gaps, and differences in documentation presentation, forming the basis of the Results and Discussion sections below.

RESULTS

Dossier Structure: CTD versus ATD

The CTD comprises five modules with a globally harmonised structure (Module 1: Administrative Information; Module 2: Summaries and Overviews; Module 3: Quality; Module 4: Non-clinical Study Reports; Module 5: Clinical Study Reports). The ATD, while inspired by the CTD, is organised into four parts (Part I: Administrative Data; Part II: Quality; Part III: Non-clinical; Part IV: Clinical) and does not retain a standalone summaries-and-overviews module equivalent to CTD Module 2, instead embedding overview and summary content within each part. Table 1 summarises the module-wise correspondence and the key structural difference at each level.

Table 1. Module-wise structural comparison between the ICH CTD and the ASEAN ATD.

Comparative Submission Requirements

Beyond module structure, the two formats differ in submission logistics and lifecycle expectations, summarised in Table 2.

Table 2. Comparative submission requirements between CTD and ATD pathways.

Review Timelines and Regulatory Expectations

Because review-timeline data are not uniformly published across ASEAN member states, this comparison is presented qualitatively rather than with specific day counts (Table 3).

Table 3. Qualitative comparison of review timeline predictability and regulatory expectations.

Illustrative Quality and Stability Data Presentation

Table 4. Illustrative compiled example of typical letrozole drug substance specifications.

Table 5. Illustrative compiled example of typical finished-product (letrozole tablets, 2.5 mg) specifications.

Table 6. Illustrative compiled accelerated stability profile, letrozole drug substance (40°C ± 2°C / 75% ± 5% RH, hypothetical dataset).

Table 7. Illustrative compiled long-term stability profile, letrozole drug substance (30°C ± 2°C / 60% ± 5% RH, hypothetical dataset, selected time points).

On the basis of this illustrative dataset, a hypothetical drug-substance re-test period of 60 months at 30°C ± 2°C / 60% ± 5% RH would be supportable, subject to confirmation with real study data.

Table 8. Illustrative compiled stability profile, letrozole finished product (accelerated: 40°C ± 2°C / 75% ± 5% RH; long-term: 30°C ± 2°C / 65% ± 5% RH, hypothetical dataset, selected time points).

On this illustrative basis, a hypothetical finished-product shelf life of 36 months at 30°C ± 2°C / 65% ± 5% RH would be supportable, subject to confirmation with real study data. Authors intending to submit real stability data should replace Tables 6-8 with the actual dataset and describe batch numbers, analytical methodology, and data-ownership/ethical considerations as applicable.

DISCUSSION

Why the Structural Differences Matter in Practice

The module-wise comparison in Table 1 is not merely a matter of document organization. Because the ATD embeds summary content within each part rather than centralizing it in a dedicated module, reviewers in different ASEAN member states may expect different levels of synthesis before reaching the detailed quality or clinical sections, which can make it harder for a single global summary document to satisfy every national authority without local adaptation. Similarly, the CTD's mandatory eCTD submission enforces a consistent lifecycle-management discipline (defined sequence numbers, standardized granularity of documents) that the ATD's mixed paper/electronic practice does not yet guarantee, so companies preparing an ATD submission cannot assume that a single electronic package will be equally usable across all target markets.

Regulatory Challenges Identified

Variability across ASEAN member states: despite the ATD's harmonization intent, individual ASEAN countries maintain distinct interpretations of dossier requirements, forcing companies to tailor submissions per country and increasing preparation complexity.

Inconsistent data-depth expectations: ATD flexibility in quality, non-clinical and clinical data depth can create ambiguity about sufficiency, whereas the CTD's comprehensive, standardized expectations leave less room for interpretation, but also less flexibility for smaller manufacturers.

Region-specific data needs: ASEAN regulators may require local clinical or post-marketing surveillance data that is not part of a standard ICH-aligned package, creating additional work for companies accustomed to CTD requirements.

Electronic submission disparity: the CTD's eCTD mandate contrasts with uneven ATD electronic-submission infrastructure, complicating dossier lifecycle management across ASEAN markets.

Regulatory capacity and review timelines: resource constraints and varying expertise among ASEAN authorities can prolong review and produce inconsistent feedback, relative to the more established review infrastructure typical of ICH-aligned authorities.

Balancing flexibility and rigour in data presentation: reconciling ATD flexibility with CTD-level rigout for the same underlying scientific data package often requires additional data bridging or supplementary documentation.

Country-specific administrative and legal requirements: diverse declarations, certificates and labelling standards across ASEAN countries add complexity beyond the more uniform CTD Module 1.

Market access and commercial strategy impact: inconsistent requirements and unpredictable timelines can delay market entry and increase costs for companies seeking approval across both ATD and CTD jurisdictions.

Illustrative Case Scenarios

Editorial note: the scenarios below are hypothetical, composite illustrations built from the general patterns described in the regulatory literature reviewed for this article. They are not accounts of a specific, identifiable company or submission, and no proprietary or confidential information is described. Authors wishing to include real, citable case studies should replace this section with properly referenced, anonymized examples.

Illustrative scenario - ICH-aligned submission: a manufacturer preparing an eCTD-format letrozole dossier for a stringent ICH-aligned authority would typically compile comprehensive clinical, quality and non-clinical documentation under the standard five-module structure. The main anticipated challenges would be aligning multi-centre clinical data with ICH guidelines and maintaining cross-module consistency; the harmonised structure would be expected to support a relatively predictable review pathway.

Illustrative scenario - ASEAN submission: a manufacturer submitting the same underlying scientific data as an ATD dossier across several ASEAN authorities would likely encounter varying local data and administrative expectations, a mix of paper and electronic submission requirements, and inconsistent interpretation of quality/non-clinical data depth, potentially producing staggered approval timelines and higher administrative burden despite comparable underlying science.

Practical Implications for the Pharmaceutical Industry

For regulatory affairs teams, the practical implication of the comparison above is that a single global dossier package cannot be assumed to transfer directly between CTD and ATD submissions without country-level review. Building a master file that separates centrally harmonised content (Module 3/Part II quality data, non-clinical summaries) from jurisdiction-specific administrative and local-data requirements would reduce duplication of effort. Early engagement with national ASEAN authorities to confirm current electronic-submission capability and locally expected data depth is also likely to reduce late-stage query cycles, particularly for a sensitivity-dependent, narrow-therapeutic-index oncology product such as letrozole.

CONCLUSION

This review presents a comparative evaluation of regulatory challenges associated with letrozole dossier submissions across the ASEAN Technical Dossier and ICH Common Technical Document formats. The CTD, globally harmonised and modularised into five distinct modules, demands comprehensive, standardised data packages with mandatory electronic submission (eCTD) in most ICH-aligned jurisdictions. The ATD, while inspired by the CTD, offers a more flexible structure tailored to ASEAN markets, allowing variation in data depth and format. This flexibility, however, is also the source of the harmonisation gaps identified in this review: variability in member-state requirements, uneven electronic-submission infrastructure, and ambiguity in data-depth expectations, which together can extend and complicate approval timelines relative to ICH-aligned regions, with downstream effects on market access and commercial strategy.

Based on these findings, the following recommendations are proposed for harmonisation:

●       Strengthen ASEAN regulatory capacity by enhancing expertise and resources within national authorities to reduce variability and improve review predictability.

●       Develop clearer, ATD-specific guidance on data-depth expectations to minimise ambiguity and improve consistency across member states.

●       Advance standardised electronic-submission infrastructure across ASEAN member states, aligned with global eCTD practice.

●       Encourage regional cooperation through mutual recognition and reliance mechanisms to streamline dossier review.

●       Promote continuous dialogue between regulatory authorities and pharmaceutical sponsors to address evolving scientific and regulatory challenges.

Addressing these areas could improve regulatory compliance for letrozole, and by extension other pharmaceutical products, facilitating faster approvals, better market access, and improved patient outcomes.

ACKNOWLEDGEMENT

The authors acknowledge Bhupal Nobles' College of Pharmacy, Bhupal Nobles' University, Udaipur, for institutional support during the preparation of this manuscript.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1. Mouridsen H, Perez-Carrion R, Becquart D, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. J Clin Oncol. 2001;19:2596-606.

2. Joylein L, Adhikari B, Kottayi MC, et al. Comparison of regulatory dossier requirements for marketing authorization of generic solid dosage forms in the United States and Europe. J Generic Med. 2021;17:174-82.

3. Lipton A, Grossberg H, Kambic KB, et al. Letrozole: a phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer. 1995;75:2132-8.

4. Pfister CU, De Braud F, Hornberger U, et al. Effect of age and single versus multiple dose pharmacokinetics of letrozole in breast cancer patients. Biopharm Drug Dispos. 2001;22:191-7.

5. Geisler J, Aas T, Duong NK, et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res. 2008;14:6330-5.

6. Dansie LS, Ardal C, Odoch WD. Industrial perceptions of medicines regulatory harmonization in the East African Community. PLoS One. 2019;14:e0218617.

7. Goss PE. Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treat. 2007;105:45-53.

8. Priyadarsini S, Lahoti SR. Quality by design: optimization of letrozole solid lipid nanoparticle for breast cancer. Indian J Pharm Educ Res. 2022;56:1013-24.

9. Buzdar AU. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women. J Clin Oncol. 2004;22:3199-200.

10. Cohen MH, Johnson JR, Li N, et al. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. Clin Cancer Res. 2002;8:665-9.

11. Ekeigwe AA. Drug manufacturing and access to medicines: the West African story. AAPS Open. 2019;5:1-5.

12. Jose J, Rajput A, Nikshitha M. Regulatory affairs: historical overview, authorities, and role in drug approval. In: Dosage Forms, Formulation Developments and Regulations. 2024. p. 99-138.

13. Kashoki M, Hanaizi Z, Yordanova S, et al. A comparison of EMA and FDA decisions for new drug marketing applications 2014-2016. Clin Pharmacol Ther. 2019;107:195-202.

14. Katkar RB, Bagali RS, Kulkarni AS, et al. A review: comparative study in CTD dossier for US, EU and Australia market. 2021.

15. Liang C, Zhang Y, An P, et al. Safety profile of letrozole in the real world: a disproportionality analysis of FAERS database and systematic review of case reports. Expert Opin Drug Saf. 2025.

16. Ncube BM, Dube A, Ward K. Establishment of the African Medicines Agency: progress, challenges and regulatory readiness. J Pharm Policy Pract. 2021;14:29.

17. Pourraz J. Making medicines in post-colonial Ghana: state policies, technology transfer and pharmaceuticals market. Soc Sci Med. 2022;311:115360.

18. Randeria JA, Dedania R, Dedania Z, et al. Regulatory requirements for dossier submission in African countries. Int J Drug Regul Aff. 2018;6:14-21.

19. Samuel N, Verma S. Cross-comparison of cancer drug approvals at three international regulatory agencies. Curr Oncol. 2016;23:454-60.

20. Scott LJ, Keam SJ. Letrozole. Drugs. 2006;66:353-62.

21. Wagh S, Waghmare SU, Narode P, et al. Understanding regulatory affairs in the pharmaceutical industry. 2024;2:1052-67.